Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Beyond ABVD: Targeted agents and strategies in first line treatment of elderly Hodgkin Lymphoma patients

Questionnaire

To access this module, please register or login:

Login or Register

Beyond ABVD: Targeted agents and strategies in first line treatment of elderly Hodgkin Lymphoma patients
Beyond ABVD: Targeted agents and strategies in first line treatment of elderly Hodgkin Lymphoma patients

Time limit: 0

Questionnaire Summary

0 of 5 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 5 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please read/watch the module carefully and try once more!
(Only two tries are allowed)
Congratulations on successfully completing this FREE CPD module!
- For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile
- For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.
Please note you will no longer receive a pass confirmation email. Your activity automatically downloads on to your deNovo Medica profile.
Visit your profile HERE to find all your CPD certificates and activities completed.

1
2
3
4
5

Current
Review
Answered
Correct
Incorrect

Question 1 of 5
1. Question
1. Globally the incidence of HL is highest in people aged 20 to 34 years, but patients over the age of 75 years account for:
A. 15% of the total HL population
Correct Incorrect Correct answer

B. 20% of the total HL population
Correct Incorrect Correct answer

C. 30% of the total HL population
Correct Incorrect Correct answer
Question 2 of 5
2. Question
2. In the ECHELON 1 trial of Brentuximab vedotin (BV+AVD), the 5-year PFS of patients 60 years and older:
A. 60.5%
Correct Incorrect Correct answer

B. 67.1%
Correct Incorrect Correct answer

C. 83.0%
Correct Incorrect Correct answer
Question 3 of 5
3. Question
3. In the presentation by Dr Sureda, the use of bleomycin is not advocated beyond 2 cycles in older patients based on findings from the HD10 and HD13 clinical trials, because?
A. Bleomycin lung toxicity is increased with increasing age
Correct Incorrect Correct answer

B. Increasing cycles of ABVD to 4 cycles, result in 10% of older patients developing lung toxicity
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer
Question 4 of 5
4. Question
4. Chemotherapy remains important, also for elderly patients, as is shown in the study of 2 500 patients over the age of 65 years with early HL where delivery of a full chemotherapy regimen was associated with significantly lower mortality.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 5 of 5
5. Question
5. In advanced-stage classic HL the combination of Brentuximab vedotin with chemotherapy in the first line treatment of elderly patients in the HD21 trial, resulted in:
A. Increased PFS rates
Correct Incorrect Correct answer

B. Better tolerance
Correct Incorrect Correct answer

C. Less treatment-related morbidity
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

All Rights Reserved 2025 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?